Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products

Severe acute respiratory syndrome coronavirus 2 infected patients, receiving background anti-CD20 therapy, were treated with convalescent plasma or plasma-based products. Eight patients were included in the study, presenting with prolonged disease course and delayed viral clearance. CP/plasma-based...

Descripción completa

Detalles Bibliográficos
Autores principales: Kenig, Ariel, Ishay, Yuval, Kharouf, Fadi, Rubin, Limor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024218/
https://www.ncbi.nlm.nih.gov/pubmed/33838340
http://dx.doi.org/10.1016/j.clim.2021.108723
_version_ 1783675267386966016
author Kenig, Ariel
Ishay, Yuval
Kharouf, Fadi
Rubin, Limor
author_facet Kenig, Ariel
Ishay, Yuval
Kharouf, Fadi
Rubin, Limor
author_sort Kenig, Ariel
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 infected patients, receiving background anti-CD20 therapy, were treated with convalescent plasma or plasma-based products. Eight patients were included in the study, presenting with prolonged disease course and delayed viral clearance. CP/plasma-based products were offered as an add-on therapy to standard medical treatment. All patients showed remarkable clinical and laboratory improvement. In addition, polymerase chain reaction from nasopharyngeal swabs rapidly converted to negative following plasma administration. This study emphasizes the therapeutic efficacy of convalescent plasma and plasma-based products in a subgroup of immunocompromised patients with iatrogenic B-cell depletion.
format Online
Article
Text
id pubmed-8024218
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-80242182021-04-07 Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products Kenig, Ariel Ishay, Yuval Kharouf, Fadi Rubin, Limor Clin Immunol Article Severe acute respiratory syndrome coronavirus 2 infected patients, receiving background anti-CD20 therapy, were treated with convalescent plasma or plasma-based products. Eight patients were included in the study, presenting with prolonged disease course and delayed viral clearance. CP/plasma-based products were offered as an add-on therapy to standard medical treatment. All patients showed remarkable clinical and laboratory improvement. In addition, polymerase chain reaction from nasopharyngeal swabs rapidly converted to negative following plasma administration. This study emphasizes the therapeutic efficacy of convalescent plasma and plasma-based products in a subgroup of immunocompromised patients with iatrogenic B-cell depletion. Elsevier Inc. 2021-06 2021-04-07 /pmc/articles/PMC8024218/ /pubmed/33838340 http://dx.doi.org/10.1016/j.clim.2021.108723 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Kenig, Ariel
Ishay, Yuval
Kharouf, Fadi
Rubin, Limor
Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products
title Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products
title_full Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products
title_fullStr Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products
title_full_unstemmed Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products
title_short Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products
title_sort treatment of b-cell depleted covid-19 patients with convalescent plasma and plasma-based products
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024218/
https://www.ncbi.nlm.nih.gov/pubmed/33838340
http://dx.doi.org/10.1016/j.clim.2021.108723
work_keys_str_mv AT kenigariel treatmentofbcelldepletedcovid19patientswithconvalescentplasmaandplasmabasedproducts
AT ishayyuval treatmentofbcelldepletedcovid19patientswithconvalescentplasmaandplasmabasedproducts
AT kharouffadi treatmentofbcelldepletedcovid19patientswithconvalescentplasmaandplasmabasedproducts
AT rubinlimor treatmentofbcelldepletedcovid19patientswithconvalescentplasmaandplasmabasedproducts

Ejemplares similares